SAN
DIEGO, June 21, 2022 /PRNewswire/ -- Kintara
Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a
biopharmaceutical company focused on the development of new solid
tumor cancer therapies, today announced that President and CEO
Robert E. Hoffman will present a
corporate overview at the Alliance Global Partners Summer
Healthcare Conference. The conference is being held virtually on
June 21 – 22, 2022.
Mr. Hoffman will be available for one-on-one meetings. For more
information, please contact your registered AGP representative or
agpevents@allianceg.com.
ABOUT KINTARA
Located in San Diego,
California, Kintara is dedicated to the development of novel
cancer therapies for patients with unmet medical needs. Kintara is
developing two late-stage, Phase 3-ready therapeutics for clear
unmet medical needs with reduced risk development programs.
The two programs are VAL-083 for Glioblastoma (GBM) and REM-001 for
Cutaneous Metastatic Breast Cancer (CMBC).
VAL-083 is
a "first-in-class," small-molecule chemotherapeutic with
a novel mechanism of action that has demonstrated clinical activity
against a range of cancers, including central nervous system,
ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head
and neck) in U.S. clinical trials sponsored by the National Cancer
Institute (NCI). Based on Kintara's internal research programs and
these prior NCI-sponsored clinical studies, Kintara is
currently advancing VAL-083 in the Global Coalition for Adaptive
Research registrational phase 2/3 clinical trial titled
Glioblastoma Adaptive Global Innovative Learning Environment (GBM
AGILE) Study to support the development and commercialization of
VAL-083 in GBM.
Kintara is also advancing its proprietary,
late-stage photodynamic therapy platform that holds promise as a
localized cutaneous, or visceral, tumor treatment as well as in
other potential indications. REM-001 therapy has been
previously studied in four Phase 2/3 clinical trials in patients
with CMBC who had previously received chemotherapy and/or failed
radiation therapy. With clinical efficacy to date of 80% complete
responses of CMBC evaluable lesions, and with an existing robust
safety database of approximately 1,100 patients across multiple
indications, Kintara is advancing the REM-001 CMBC
program to late-stage pivotal testing.
For more information, please
visit www.kintara.com or follow us on Twitter
at @Kintara_Thera, Facebook and LinkedIn.
SAFE HARBOR STATEMENT
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995, including statements
regarding the status of the Company's clinical trials and the GBM
AGILE Study. Any forward-looking statements contained herein are
based on current expectations but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the impact
of the COVID-19 pandemic on the Company's operations and clinical
trials; the Company's ability to develop, market and sell products
based on its technology; the expected benefits and efficacy of the
Company's products and technology; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC, including the Company's Annual Report on Form 10-K
for the year ended June 30, 2021, the
Company's Quarterly Reports on Form 10-Q, and the Company's Current
Reports on Form 8-K.
CONTACTS
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-alliance-global-partners-summer-healthcare-conference-301571910.html
SOURCE Kintara Therapeutics